In addition, the circulating IGF2BP3 protein levels, recently detected in serum from prostate cancer and renal cell carcinoma patients, were found to be associated with a significantly higher risk of cancer-specific death or relapse (Szarvas et al., 2014; Tschirdewahn et al., 2019). This evidence concerns the gene IGF2BP3 and cancer.